Overview of U.S. Patent 9,993,466
U.S. Patent 9,993,466, titled “Methods of treating diseases using antibody-drug conjugates,” was issued on June 12, 2018. The patent primarily covers antibody-drug conjugate (ADC) compositions, methods of making them, and their use in treating specific diseases, notably certain cancers.
Scope and Claims Analysis
Claims Overview: The patent contains 36 claims, with independent claims 1 and 31. These focus on ADC compositions with specific antibody and linker-drug components, methods for preparing such conjugates, and methods for treating cancer using the ADCs.
Key Aspects of Claims:
- Antibody Component: Targeted to antigens such as CD22 or CD19, prominent in hematologic malignancies.
- Linker Technology: Emphasizes cleavable linkers, including balancing stability in circulation and payload release at tumor sites.
- Payload: Incorporates cytotoxic agents, notably pyrrolobenzodiazepine (PBD) dimers, or derivatives as the drug component.
- Conjugation Chemistry: Employs site-specific conjugation techniques, such as engineered cysteines, to ensure homogeneity and stability.
- Methods of Use: Covers administering ADCs for treatment of B cell malignancies and other related cancers.
Novelty and Inventive Step: The claims distinguish themselves by combining specific antibody targets with PBD-based payloads, coupled with site-specific conjugation methods. This combination aims to optimize therapeutic index over previous ADCs, such as those utilizing calicheamicin or other payloads.
Patent Landscape and Prior Art
Related Patents and Applications:
- Amgen Inc. (e.g., US Patent 9,707,141) for anti-CD22 ADCs using pyrrolobenzodiazepine payloads.
- Seattle Genetics /ADC Technology: Several foundational patents, e.g., US Patent 8,603,483, covering ADC linkers and conjugation.
- Roche / Genentech: Patents on HER2-targeted ADCs with different linkers and payloads, such as trastuzumab emtansine (T-DM1).
Patent Family and Filing Timeline:
- Filing date: June 3, 2016.
- Priority applications in the family extend coverage into Europe, Japan, and other jurisdictions, with similar claims.
Overlap and Differentiation:
- The claims in 9,993,466 are distinguished by specific antibody sequences, the conjugation sites, and the payload chemistry. While prior ADCs utilize different payloads (e.g., maytansinoids, calicheamicins), the PBD payloads confer distinct potency and mechanism.
Active Patent Ecosystem:
- Numerous pending applications and granted patents exist for site-specific conjugation, antibody targeting methods, and payload chemistry. Patents related to ADC linker stability and cleavability are also relevant, creating a dense landscape.
Legal and Commercial Implications
Patent Term and Rights: The patent provides exclusivity until at least 2036, considering patent term adjustments. Licensing or non-infringement strategies will need to navigate the coexistence of multiple patents covering ADC components.
Potential Infringements: Companies developing ADCs targeting the same antigens with similar chemistry must analyze claims for potential infringement, especially around conjugation techniques and payload examples.
Critical Jurisdictions: While the patent primarily protects U.S. rights, similar claims are filed internationally, with jurisdiction-specific differences. European counterparts, such as EP patents, may have varying scopes.
Conclusion
U.S. Patent 9,993,466 covers a specific niche of ADCs incorporating PBD payloads, site-specific conjugation, and antibody specificity for cancer treatment. Its claims differentiate through the combination of payload chemistry and conjugation methods, positioning it as a potentially strong patent within the ADC landscape. Competitors targeting similar indications or payloads must conduct detailed claim-by-claim infringement analyses.
Key Takeaways
- The patent covers ADC compositions targeting B cell malignancies with conjugation techniques ensuring homogeneity.
- Claims encompass specific antibody targets, payloads, and conjugation chemistries, emphasizing PBD payloads.
- The patent landscape is crowded but distinct, with differentiation based on payload and linkers.
- Licensing strategies must consider broader patent environment, especially related to conjugation technologies.
- The patent is enforceable until 2036, with international family coverage extending rights globally.
FAQs
1. What diseases could this patent potentially impact?
Primarily hematologic cancers like non-Hodgkin lymphoma and other B cell malignancies, given the antibody targets and payloads.
2. How does the payload in this patent differ from other ADC payloads?
It employs pyrrolobenzodiazepine (PBD) dimers, which are highly potent DNA cross-linking agents, differing from maytansinoids or calicheamicins used in other ADCs.
3. Are there existing drugs based on this patent's technology?
No FDA-approved drugs directly cite this patent, but ADCs with similar components are in clinical development or approved, such as bi-specific ADCs with PBD payloads.
4. What are the main challenges in developing ADCs covered by this patent?
Ensuring stability, minimizing off-target toxicity, and manufacturing homogenous conjugates are key technical hurdles.
5. How does the conjugation method influence patentability?
Site-specific conjugation enhances homogeneity, offering a patentable advantage over traditional random conjugation techniques, and is a core claim element.
References
[1] U.S. Patent No. 9,993,466.
[2] Related prior art and patent applications (e.g., US Patent 9,707,141).
[3] FDA labels and product data for ADCs.
[4] Literature on PBD-based ADCs and conjugation strategies.
